RCT | Adjunctive transdermal cannabidiol no better than placebo for drug-resistant focal epilepsy.
12 Jul, 2022 | 12:54h | UTC
Commentary on Twitter
In this randomized clinical trial, transdermal cannabidiol was well-tolerated and safe, but did not decrease seizure frequency at week 12 of the double-blind period among the placebo, 195-mg cannabidiol, and 390-mg cannabidiol treatments. https://t.co/lR3kEzPE5T
— JAMA Network Open (@JAMANetworkOpen) July 8, 2022